LDL-胆固醇并非冠心病或急性冠脉综合征的唯一有临床意义的生物标志物。
LDL-Cholesterol Is Not the Only Clinically Relevant Biomarker for Coronary Artery Disease or Acute Coronary Syndrome.
机构信息
Boston University's and National Heart, Lung, and Blood Institute's Framingham Study, Framingham, Massachusetts, USA.
Sections of Preventive Medicine and Epidemiology, and Cardiovascular Medicine, Department, School of Medicine, Department of Epidemiology, Boston University Schools of Medicine and Public Health, Boston, Massachusetts, USA.
出版信息
Clin Pharmacol Ther. 2018 Aug;104(2):232-234. doi: 10.1002/cpt.1126. Epub 2018 Jul 13.
Abstract
Coronary artery disease (CAD) is a progressive disorder and its risk is best determined using multiple biomarkers and risk factors. Many novel biomarkers have been shown to improve cardiovascular disease risk beyond that of the traditional risk factors, including polygenic risk scores, small very low-density lipoprotein (VLDL), ApoB, triglycerides (TG), non-HDL-c, lipoprotein (a) (Lp(a)), coronary calcium scores, C-reactive protein (CRP), B-type natriuretic peptide (BNP), troponins, and many other novel biomarkers that have been measured using high throughput assays.
摘要
冠心病（CAD）是一种进行性疾病，其风险最好通过多种生物标志物和危险因素来确定。许多新型生物标志物已被证明可改善心血管疾病风险，超过传统危险因素，包括多基因风险评分、小而极低密度脂蛋白（VLDL）、载脂蛋白 B（ApoB）、甘油三酯（TG）、非高密度脂蛋白胆固醇（non-HDL-c）、脂蛋白（a）（Lp(a)）、冠状动脉钙评分、C 反应蛋白（CRP）、B 型利钠肽（BNP）、肌钙蛋白和许多其他使用高通量检测方法测量的新型生物标志物。
相似文献
1
LDL-Cholesterol Is Not the Only Clinically Relevant Biomarker for Coronary Artery Disease or Acute Coronary Syndrome.LDL-胆固醇并非冠心病或急性冠脉综合征的唯一有临床意义的生物标志物。
Clin Pharmacol Ther. 2018 Aug;104(2):232-234. doi: 10.1002/cpt.1126. Epub 2018 Jul 13.
2
LDL-Cholesterol Is the Only Clinically Relevant Biomarker for Atherosclerotic Cardiovascular Disease (ASCVD) Risk.低密度脂蛋白胆固醇是动脉粥样硬化性心血管疾病（ASCVD）风险唯一具有临床相关性的生物标志物。
Clin Pharmacol Ther. 2018 Aug;104(2):235-238. doi: 10.1002/cpt.1125. Epub 2018 Jul 13.
3
The effect of lipid and inflammatory profiles on the morphological changes of lipid-rich plaques in patients with non-ST-segment elevated acute coronary syndrome: follow-up study by optical coherence tomography and intravascular ultrasound.脂质和炎症特征对非 ST 段抬高急性冠状动脉综合征患者富含脂质斑块形态变化的影响：光学相干断层成像术和血管内超声随访研究。
JACC Cardiovasc Interv. 2010 Jul;3(7):766-72. doi: 10.1016/j.jcin.2010.05.001.
4
Association between the serum lipoprotein-associated phospholipase A level and acute coronary syndrome.血清脂蛋白相关磷脂酶 A 水平与急性冠状动脉综合征的关系。
Cardiovasc J Afr. 2023;34(5):273-277. doi: 10.5830/CVJA-2022-056. Epub 2023 Jan 11.
5
Lipoprotein(a) screening in young and middle-aged patients presenting with acute coronary syndrome.对出现急性冠脉综合征的中青年患者进行脂蛋白(a)筛查。
Cardiol J. 2019;26(5):511-518. doi: 10.5603/CJ.a2018.0106. Epub 2018 Sep 20.
6
Prevalence, clinical features and prognosis of familial hypercholesterolemia in Chinese Han patients with acute coronary syndrome after a coronary event: a retrospective observational study.在中国汉族急性冠脉综合征患者冠脉事件后，家族性高胆固醇血症的患病率、临床特征和预后：一项回顾性观察研究。
BMC Cardiovasc Disord. 2024 Mar 5;24(1):144. doi: 10.1186/s12872-024-03803-4.
7
Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease.稳定型冠状动脉疾病患者血浆磷脂酶A2浓度与脂蛋白亚组分之间的关系。
Clin Chim Acta. 2015 Jun 15;446:195-200. doi: 10.1016/j.cca.2015.04.032. Epub 2015 Apr 28.
8
Age, Sex, and Cardiovascular Risk Attributable to Lipoprotein Cholesterol Among Chinese Individuals with Coronary Artery Disease: A Case-Control Study.年龄、性别与脂蛋白胆固醇在中国冠心病患者心血管风险归因：一项病例对照研究。
Metab Syndr Relat Disord. 2019 May;17(4):223-231. doi: 10.1089/met.2018.0067. Epub 2019 Feb 5.
9
Elevated small dense low-density lipoprotein cholesterol as a predictor for future cardiovascular events in patients with stable coronary artery disease.升高的小而密低密度脂蛋白胆固醇作为稳定型冠状动脉疾病患者未来心血管事件的预测指标。
J Atheroscler Thromb. 2014;21(8):755-67. doi: 10.5551/jat.23465. Epub 2014 Apr 8.
10
Changes in triglyceride, HDL-C, and non-HDL-C levels in patients with acute coronary syndrome.急性冠状动脉综合征患者甘油三酯、高密度脂蛋白胆固醇和非高密度脂蛋白胆固醇水平的变化。
Wien Klin Wochenschr. 2016 Dec;128(23-24):858-863. doi: 10.1007/s00508-016-1035-4. Epub 2016 Jul 5.
引用本文的文献
1
Bridging aging, immunity, and atherosclerosis: novel insights into senescence-related genes.连接衰老、免疫与动脉粥样硬化：衰老相关基因的新见解
Front Immunol. 2025 Jun 19;16:1557266. doi: 10.3389/fimmu.2025.1557266. eCollection 2025.
2
Serological Evidence of Hepatitis B and E and Dengue Coinfection in Chadian Patients and Impact on Lipidemia Profile.乍得患者中乙型肝炎、戊型肝炎和登革热合并感染的血清学证据及其对血脂谱的影响。
Int J Hepatol. 2022 Sep 16;2022:8373061. doi: 10.1155/2022/8373061. eCollection 2022.
3
The Effect of Three Mediterranean Diets on Remnant Cholesterol and Non-Alcoholic Fatty Liver Disease: A Secondary Analysis.三种地中海饮食对残余胆固醇和非酒精性脂肪肝的影响：二次分析。
Nutrients. 2020 Jun 4;12(6):1674. doi: 10.3390/nu12061674.
4
Serum Triglyceride Lipase Concentrations are Independent Risk Factors for Coronary Artery Disease and In-Stent Restenosis.血清三酰甘油脂肪酶浓度是冠状动脉疾病和支架内再狭窄的独立危险因素。
J Atheroscler Thromb. 2019 Sep 1;26(9):762-774. doi: 10.5551/jat.46821. Epub 2019 Jan 17.
5
Correlations between Body Mass Index, Plasma High-Sensitivity C-Reactive Protein and Lipids in Patients with Schizophrenia.精神分裂症患者的体重指数、血浆高敏 C 反应蛋白与血脂的相关性。
Psychiatr Q. 2019 Mar;90(1):101-110. doi: 10.1007/s11126-018-9606-3.
本文引用的文献
1
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.卡那奴单抗治疗动脉粥样硬化疾病的抗炎疗法。
N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27.
2
Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol.低密度脂蛋白胆固醇水平较低个体中动脉粥样硬化性脂蛋白对心血管疾病及残余风险的影响因素
J Am Heart Assoc. 2017 Jul 21;6(7):e005549. doi: 10.1161/JAHA.117.005549.
3
How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL.如何评估和管理除低密度脂蛋白之外与血脂改变相关的心血管风险。
Atheroscler Suppl. 2017 Apr;26:16-24. doi: 10.1016/S1567-5688(17)30021-1.
4
Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart Disease.基于蛋白质的稳定型冠心病患者心血管结局风险评分的开发和验证。
JAMA. 2016 Jun 21;315(23):2532-41. doi: 10.1001/jama.2016.5951.
5
Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium.肌钙蛋白I与普通人群心血管风险预测：BiomarCaRE联盟
Eur Heart J. 2016 Aug 7;37(30):2428-37. doi: 10.1093/eurheartj/ehw172. Epub 2016 May 12.
6
Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials.遗传风险、冠心病事件与他汀类药物治疗的临床获益：一项对一级和二级预防试验的分析
Lancet. 2015 Jun 6;385(9984):2264-2271. doi: 10.1016/S0140-6736(14)61730-X. Epub 2015 Mar 4.
7
2013 ACC/AHA guideline on the assessment of cardiovascular risk.2013年美国心脏病学会/美国心脏协会心血管风险评估指南。
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2886. doi: 10.1016/j.jacc.2014.02.606. Epub 2014 Apr 23.
8
Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study.基于定量检测冠状动脉粥样硬化的冠心病风险分层、鉴别和再分类改善：Heinz Nixdorf 回顾研究。
J Am Coll Cardiol. 2010 Oct 19;56(17):1397-406. doi: 10.1016/j.jacc.2010.06.030.
9
B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies.B 型利钠肽与心血管风险：40 项前瞻性研究的系统评价和荟萃分析。
Circulation. 2009 Dec 1;120(22):2177-87. doi: 10.1161/CIRCULATIONAHA.109.884866. Epub 2009 Nov 16.
Zotero 插件